Health
Calliditas Therapeutics AB to Present Exploratory Biomarker and Post-Hoc NefIgArd Analyses at the World Congress of Nephrology
Calliditas Therapeutics AB, an Asahi Kasei company, announced today that new data from the Phase 3 NefIgArd study in patients with primary immunoglobulin A nephropathy (IgAN) will be presented at the 2026 World Congress of Nephrology (WCN), taking place from March 28 to 31 in Yokohama, Japan.
About this update from Asahi Kasei Corporation
[{"type":"list","items":[{"val":[{"type":"text","content":"Calliditas will present new secondary, biomarker, and mechanistic analyses from the Phase 3 NefIgArd study at the 2026 World Congress of Nephrology.","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"Data further support Nefecon's gut–targeted, disease–modifying mechanism of action in IgA nephropathy.","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"Calliditas to present seven posters and sponsor a scientific symposium highlighting the evolving IgAN treatment paradigm.","length":121,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":375,"olType":false},{"type":"text","content":"STOCKHOLM, March 30, 2026 /PRNewswire/ -- Calliditas Therapeutics AB, an Asahi Kasei company, announced today that new data from the Phase 3 NefIgArd study in patients with primary immunoglobulin A nephropathy (IgAN) will be presented at the 2026 World Congress of Nephrology (WCN), taking place from March 28 to 31 in Yokohama, Japan.","length":335,"tagName":"p"},{"type":"image","alt":"Calliditas Therapeutics","displaySize":"","headline":null,"caption":"Calliditas Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":115,"url":"https://media.zenfs.com/en/prnewswire.com/93fa0c887e12ea5a3836f2985fbaaf3d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2LHO9_R.EnV9o_yzoDrlgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIwMw--/https://media.zenfs.com/en/prnewswire.com/93fa0c887e12ea5a3836f2985fbaaf3d","width":400,"height":115}},"href":"https://mma.prnewswire.com/media/2944503/Calliditas_Therapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Nefecon's approval status, labeled indication, and availability vary globally. It is approved in the United States where it is marketed as TARPEYO® (budesonide) delayed-release capsules. It is available in Europe where it is marketed as Kinpeygo® by STADA Arzneimittel AG and in select countries in Asia, including Mainland China, Hong Kong, Macau, Taiwan, Singapore, and South Korea by Everest Medicines. It is also the subject of clinical trials in Japan by Viatris Pharamaceticals Japan Inc.","length":498,"tagName":"p"},{"type":"text","content":"The presentations will highlight secondary analyses from the Phase 3 NefIgArd study evaluating Nefecon, its effects on serum biomar...